ENDOSCOPY SOLUTIONS PERFORMANCE
Last year’s comparative figures are stated in brackets.
Endoscopy Solutions sales for the quarter were up,
reflected by an organic growth of 18.0% (23.3%) and a
reported growth of 18.9% (21.7%), with a revenue of
DKK 813m (DKK 684m). Endoscopy Solutions
accounted for 59% (57%) of Ambu’s total revenue in
Q3 2023/24.
aScope™ 5 Broncho’s excellent performance, com-
pared to reusable bronchoscopes.
Gastroenterology (GI) sales growth continued, mainly
driven by Ambu’s two gastroscope solutions,
aScope™ Gastro and aScope™ Gastro Large. The GI
segment accounts for a small part of Ambu’s
Endoscopy Solutions business, representing a long-
term growth potential, with a stepwise, high-need and
niche area-based expansion approach.
Endoscopy Solutions excluding pulmonology
posted 27.6% organic growth, accounting for 50% of
Ambu’s total endoscopy revenue. The biggest growth
drivers were urology and ENT, which posted continued
high double-digit growth.
The satisfactory growth in Endoscopy Solutions was
mainly driven by Ambu’s existing solutions in the
growing single-use market.
Additionally, in Q3, Ambu strengthened its gastro-
enterology (GI) offering by obtaining European
regulatory clearance of aScope™ Duodeno 2. Having
secured North American regulatory clearance (FDA)
back in April 2024, Ambu now continues its extended
controlled market release phase in the USA and
Europe with key hospitals to evaluate clinical perfor-
mance in a real-life setting. The solution will be
available in the market from 2024/25. Globally, the
solution targets 0.4 million annual procedures.
Ear-nose-throat (ENT) and urology continued their
double-digit organic growth trajectory, due to an
increased pace of order uptakes and penetration of
new customers, especially in North America and
Europe. Otolaryngologists and urologists value the
workflow efficiencies brought forth by Ambu’s single-
use solutions, which supports the continued con-
version towards single-use in the two segments.
DRIVERS OF THE QUARTER
Pulmonology posted 9.9% organic growth for Q3,
accounting for 50% of the total endoscopy revenue,
driven by Ambu’s bronchoscopy portfolio as the
biggest growth contributor.
In line with expectations, pulmonology declined 4.0%
(on a reported basis), compared to Q2 2023/24. This
was primarily attributed to natural fluctuations of the
flu season, which is typically the most impactful during
the first half year of Ambu’s fiscal year.
During the quarter, Ambu significantly enhanced its
urology portfolio by obtaining FDA clearance for its
ureteroscopy solution, aScope™ 5 Uretero, along with
the company’s two endoscopy systems, aBox™ 2 and
aView™ 2 Advance. Ambu’s ureteroscope connects to
the same systems platform as the company’s
aScope™ 4 Cysto, and so this clearance marks an
important milestone within Ambu’s interconnected
solutions set-up, ultimately enabling U.S. urologists
and their teams to benefit from an increasingly
seamless and efficient workflow.
The new generation aScope™ Duodeno 2 constitutes
a step change from previous generations, driven by
valuable collaboration with healthcare professionals. It
is aimed to meet the unique needs of gastroenterolo-
gists performing ERCP procedures.
The aScope™ 5 Broncho HD solution continues to pro-
gress gradually, positively impacted by the transitional
pass-through (TPT) payment framework. This was
granted by the Center for Medicare & Medicaid Ser-
vices (CMS), effective as of 1 January 2024, enabling
incremental reimbursement payments for outpatient
procedures performed with Ambu’s fifth-generation
bronchoscope. TPT was granted, due to the solution’s
substantial clinical improvement, compared to existing
single-use and reusable bronchoscopy technologies.
Endoscopy Solutions
organic revenue growth
The new ureteroscopy solution is developed to meet
the need for high-quality imaging and endoscope
robustness and manoeuvrability. It is expected to
address a target market of 1m annual procedures, and
Ambu expects to begin its global launch by the end of
the 2023/24 financial year.
18.0%
The aScope™ 5 Broncho HD targets the bronchoscopy
suite, representing a new customer group for Ambu.
Feedback continues to be positive, resounding the
in Q3 2023/24
6
Company announcement no. 13 2023/24
|
30 August 2024
